Convergence in the New Health

The New Health is ushering in an era of change. Amid the mounting challenges and increasing complexities of the biopharma industry, there is an urgent need to develop cross-disciplinary cooperation, foster closer collaborations and establish strategic alliances.

A critical ingredient in redefining drug development, the concept of Convergence stresses an innovative way of thinking to overcome the multiple challenges the biopharma industry is facing. In its many forms, Convergence:

  • Drives closer collaborations to design and bring better drugs to market
  • Aligns needs and expectations to reduce healthcare costs
  • Breaks down the barriers between disparate data sources and leverages new technologies to turn bits and bytes into insights

Understanding Convergence and developing strategies to capitalize on its opportunities is critical. Featuring the latest forward-thinking material from the consulting group at Quintiles and the Executive Vision Forum 2010: Capitalizing on Convergence, this site is intended to help demonstrate the value of Convergence.

Please explore the emerging areas of Convergence below.  If you'd like to discuss how to develop a Convergence strategy, don’t hesitate to contact us.

Stakeholder Convergence

The traditional physicians' monopoly on prescribing is shifting – and drug utilization decisions are no longer predominantly based on efficacy and safety. With a renewed focus on value, pharma must understand the needs of all stakeholders in the New Health:

View key takeaways from a presentation by WellPoint's Brain Sweet on payer value assessment.

  • PlayersPayers
  • ProvidersProviders
  • PolicymakersPolicymakers
  • PatientsPatients
  • PhysiciansPhysicians
Clinical and Commercial convergence

Clinical & Commercial Convergence

Convergence is forcing these two historically disparate functions to work more collaboratively; morphing into one seamless process to bring better drugs to market. But how do we get there?

Read the latest whitepaper on Clinical and Commercial convergence.

PACeR initiative

Data & Technology Convergence

The exponential increase in data and data sources far outpaces our ability to use it for better decision-making. The pressing need to transform intuition-healthcare into precision healthcare can be realized by converging multiple data sources and supporting technologies.

Read the new whitepaper on the highly innovative PACeR initiative which bridges hospital, patient and pharma data to accelerate evidence-based medicine.

White Paper

A Blueprint for Clinical / Commercial Convergence

The development model for bio pharmaceutical companies must shift from two divergent paths to one that combines these two resources with market access strategy, information and capabilities.

Read more

Explore biopharma, payer, physician and patient viewpoints of the New Health landscape.

Go

Others also viewed